TFA-01 | Non-steroid canine osteoarthritis programView development progress
EN
Contact

TFA-01 DEVELOPMENT TIMELINE

Development progress, clearly organized by date

Starting with the latest completed, initiated or publicly disclosed work, each entry identifies the nature of the date, development dimension, progress and evidence boundary.

LATEST FIRST
LATEST FIRST
11 verifiable milestones

Timeline dates may be contract or project start dates, signed-report dates, formal filing dates or public-disclosure dates, each representing a different kind of progress. Project-period end, commissioning and study initiation are not the same as study completion.

View the five dimensions
  1. RESEARCH COLLABORATION LAUNCHED

    04 · Canine OA clinical development

    Research collaboration launched for canine osteoarthritis efficacy pilot

    The technical-services agreement for a canine osteoarthritis efficacy pilot is complete and the research collaboration has launched. The study is intended to align its design, records, statistics and reporting with applicable Chinese veterinary-drug technical requirements.

    Evidence boundary

    This milestone marks the launch of the research collaboration. It does not mean the study is complete, that efficacy or safety conclusions have been established, or that the data or product have been accepted or approved by an authority.

  2. REPORT COMPLETED

    03 · Safety & toxicology

    14-day preliminary rat toxicology report completed

    The final report for a 14-day repeat-dose preliminary study in 24 female rats received management sign-off and can inform later dose selection and formal study design.

    Evidence boundary

    This TF-15 study was not GLP regulatory toxicology or a long-term safety study. It does not establish safety in dogs, for purified Antcin A or for a final product.

  3. FILED

    01 · Molecule, mechanism & rights

    Antcin A platform cooperation framework publicly filed

    The Company disclosed the cooperation and licensing framework for TFA-01 and the Antcin A platform on Form 6-K, creating a rights milestone investors can verify.

    Evidence boundary

    A cooperation and licensing framework does not establish drug approval, efficacy, safety or commercial outcomes.

    View SEC Form 6-K
  4. AGREEMENT COMPLETED · RESEARCH ONGOING

    03 · Safety & toxicology / 02 · CMC

    Safety, toxicology, residue and formulation research program started

    Under the commissioned-research contract period, TFA-01 target-animal safety, toxicology, residue and hydrophilic nano-formulation work began its project period, with the research conducted by the Graduate Institute of Animal Vaccine Technology at National Pingtung University of Science and Technology.

    Evidence boundary

    This is the contract-stated project-period start, not evidence that every study began on that date or has been completed. The safety, toxicology, residue and standardized-formulation work remains underway, without a completed report or regulatory conclusion.

  5. STUDY STARTED

    03 · Safety & toxicology

    Dosing began in the 14-day preliminary rat safety study

    Repeat dosing began under the approved study plan to collect preliminary safety observations and inform later formal study design.

    Evidence boundary

    Study initiation is not study completion. This preliminary design cannot be extrapolated to canine or long-term safety.

  6. PUBLIC REPORT

    02 · CMC & controlled supply

    Early production and pharmacokinetic progress publicly disclosed

    Economic Daily reported on this date that the Company had completed early production-related documentation and canine pharmacokinetic work in reference to Taiwan veterinary-drug registration data requirements, and had notified the Ministry of Agriculture of the progress as part of assembling a complete application package.

    Evidence boundary

    December 12, 2025 is the public-report date, not a statutory completion or agency-review date. At this stage the Ministry was informed of progress but had not formally reviewed or accepted these materials; formal review occurs only after the complete application package is submitted. The headline’s “phase one” is not a human Phase I trial.

    View the original media report
  7. PATENT GRANTED

    02 · CMC & controlled supply

    U.S. cultivation-method and porous-carrier patent granted

    U.S. Patent No. 12,471,542 B2 was granted, covering an Antrodia cinnamomea cultivation method and a porous carrier used for cultivation.

    Evidence boundary

    The patent protects cultivation and carrier technology; it does not establish TFA-01 efficacy, safety or drug approval.

    View the public patent record
  8. STUDY COMPLETION DOCUMENTED

    01 · Molecule, mechanism & rights

    First industry-academia study on literature-derived mechanism directions completed

    The Chung Hwa University of Medical Technology final report records completion of the study on this date. The project performed preliminary experimental confirmation along literature-derived mechanism directions and summarized sample analytics, anti-inflammatory work, steroid-combination work and cancer-cell-model findings.

    Evidence boundary

    The report itself characterizes the work as preliminary and calls for batch reproducibility and further study. It does not establish direct receptor binding, formal synergy, a steroid-sparing effect, canine or human clinical efficacy, or drug approval.

  9. PLAN ANNOUNCED

    05 · Regulatory & commercialization

    Veterinary drug application initiative publicly announced

    A historical company release announced plans to advance Antcin A-based veterinary drug applications in Taiwan and China, creating a public starting point for later regulatory-data integration.

    Evidence boundary

    This was a forward-looking plan. It does not mean an application was submitted or accepted, required studies were completed, or a drug was approved.

    View the original release
  10. PUBLIC DISCLOSURE

    01 · Molecule, mechanism & rights

    Preliminary Antcin A and steroid combination work publicly released

    The Company published preliminary combination findings presented at a February 22, 2025 research event, making an early experimental observation along the literature-derived mechanism direction publicly reviewable.

    Evidence boundary

    The public material describes preliminary cell work and does not independently establish synergy, a steroid-sparing effect, direct receptor mechanism or clinical efficacy.

    View the original release
  11. INDUSTRY-ACADEMIA PROJECT PERIOD START

    01 · Molecule, mechanism & rights

    Mechanism literature confirmation and validation project

    The written collaboration period begins on January 1, 2025. Because experimental execution and the university's administrative contract process were not fully synchronized, this date is used only as the written project-period marker; study completion is anchored to the June 5, 2025 final-report record.

    Evidence boundary

    This milestone marks the Company’s first self-directed drug-related industry-academia project entering its formal project period. It does not mean the mechanism was fully proven, direct receptor binding was established, canine or human clinical efficacy was confirmed, or a drug was approved.

    View the public project record
Continuously updated

New entries use verifiable dates only. If a formal date has not been documented, the item remains pending rather than being inferred on the public timeline.